A CD3 and mesothelin targeting molecule (HPN536) has entered phase I clinical trials (NCT03872206); and preclinical models of a CD16 and mesothelin targeting bispecific molecule have demonstrated enhanced NK cell functions against triple negative breast cancer (52). The gene discussed is MSLN; the disease is triple-negative breast carcinoma.